Rousselot Biomedical to Present New Study on X-Pure at CPhI Worldwide 2019

October 28, 2019

Principal scientist and R&D project manager at Rousselot, Jos Olijve, will discuss the details of the study at the “Influence of Endotoxin on Cellular Activity” conference on day two of CPhI Worldwide from 3:20 pm to 3:50 pm in the Portalhaus, Transparenz 1 room.

Rousselot Biomedical, a collagen-based solutions manufacturer headquartered in The Netherlands, announced it will present the results of a recent study of its endotoxin-purified gelatin, X-Pure, at CPhI Worldwide on Nov. 5–7, 2019 in Frankfurt, Germany.

According to an Oct. 17, 2019 press release, the Rousselot Expertise Center and UMC Utrecht, a university hospital located in The Netherlands, conducted a study on the role of endotoxins in gelatin on mesenchymal stem cells and peripheral blood mononuclear cells and their influence on cellular activity. The teams came to the conclusion that Rousselot’s X-Pure provided a superior environment for stem cell viability and differentiation.

Principal scientist and R&D project manager at Rousselot, Jos Olijve, will discuss the details of the study at the “Influence of Endotoxin on Cellular Activity” conference on day two of CPhI Worldwide from 3:20 pm to 3:50 pm in the Portalhaus, Transparenz 1 room.

Rousselot Biomedical will also be showcasing at booth 120D21 at the event.

Source: Rousselot Biomedical